Advance of theragnosis biomarkers in lung cancer: from clinical to molecular pathology and biology

被引：6

作者：

Alidousty, Christina ^{[1
]}

Baar, Till ^{[2
]}

Heydt, Carina ^{[1
]}

Wagener-Ryczek, Svenja ^{[1
]}

Kron, Anna ^{[3
,4
,5
]}

Wolf, Juergen ^{[3
,4
,5
]}

Buettner, Reinhard ^{[1
,3
,4
]}

Schultheis, Anne Maria ^{[1
]}

机构：

[1] Univ Hosp Cologne, Inst Pathol, Cologne, Germany

[2] Univ Cologne, Fac Med, Inst Med Stat & Computat Biol, Cologne, Germany

[3] Network Genom Med, Cologne, Germany

[4] Univ Hosp Cologne, Dept Internal Med 1, Lung Canc Grp Cologne, Cologne, Germany

[5] Ctr Integrated Oncol Cologne Bonn, Cologne, Germany

来源：

JOURNAL OF THORACIC DISEASE | 2019年 / 11卷

关键词：

Non-small cell lung cancer (NSCLC); anaplastic lymphoma kinase (ALK); ALK plus -adenocarcinoma; TP53; biomarker; ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB RESISTANCE; PRACTICE GUIDELINES; TARGETED THERAPY; GROWTH-FACTOR; ALK; MUTATIONS; RECEPTOR; IDENTIFICATION; DIAGNOSIS;

D O I：

10.21037/jtd.2018.12.03

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

One distinct molecular subtype of non-small cell lung cancer (NSCLC) is defined by rearrangement of the anaplastic lymphoma kinase (ALK). The increasing knowledge over the last years has enabled the continuous improvement of ALK inhibitors; however, resistance in these patients remains a major concern. In this review, we summarize recent findings in ALK+-adenocarcinoma of the lung, highlighting the role of TP53 mutations in this specific cancer type and suggest new diagnostic strategies for the future, in order to improve patient's outcome.

引用

页码：S3 / S8

页数：6

共 50 条

[11] Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets
Capdevila, J.
Meeker, A.
Garcia-Carbonero, R.
Pietras, K.
Astudillo, A.
Casanovas, O.
Scarpa, A.
CANCER AND METASTASIS REVIEWS, 2014, 33 (01) : 345 - 351
[12] Milestones in pathology—from histology to molecular biology
Müllauer L.
memo - Magazine of European Medical Oncology, 2017, 10 (1) : 42 - 45
[13] Biomarkers of Aging: From Function to Molecular Biology
Wagner, Karl-Heinz
Cameron-Smith, David
Wessner, Barbara
Franzke, Bernhard
NUTRIENTS, 2016, 8 (06)
[14] Reducing the Risk of Overdiagnosis in Lung Cancer: A Support From Molecular Biology
Barba, Maddalena
Felsani, Armando
Rinaldi, Massimo
Giunta, Salvatore
Malorni, Walter
Paggi, Marco G.
JOURNAL OF CELLULAR PHYSIOLOGY, 2011, 226 (09) : 2213 - 2214
[15] Molecular Pathology of Primary Non-small Cell Lung Cancer
Suster, David Ilan
Mino-Kenudson, Mari
ARCHIVES OF MEDICAL RESEARCH, 2020, 51 (08) : 784 - 798
[16] Molecular Biology of Lung Cancer-A Review
Pendharkar D.
Ausekar B.V.
Gupta S.
Indian Journal of Surgical Oncology, 2013, 4 (2) : 120 - 124
[17] Summary of Presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010) Focus on Tumor Biology and Biomarkers Related to Lung Cancer
Subramanian, Janakiraman
Corrales, Luis
Soulieres, Denis
Morgensztern, Daniel
Govindan, Ramaswamy
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (02) : 399 - 403
[18] Molecular and Clinical Analysis of Predictive Biomarkers in Non-Small-Cell Lung Cancer
Passaro, A.
Palazzo, A.
Trenta, P.
Mancini, M. L.
Morano, F.
Cortesi, E.
CURRENT MEDICINAL CHEMISTRY, 2012, 19 (22) : 3689 - 3700
[19] Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance
Attarian, Shirin
Rahman, Numa
Halmos, Balazs
ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (18)
[20] Predictive molecular pathology of lung cancer in Germany with focus on gene fusion testing: Methods and quality assurance
Siemanowski, Janna
Heydt, Carina
Merkelbach-Bruse, Sabine
CANCER CYTOPATHOLOGY, 2020, 128 (09) : 611 - 621

← 1 2 3 4 5 →